心玮医疗-B(06609.HK)2024财年亏损大幅缩减88%至1200万元
格隆汇3月27日丨心玮医疗-B(06609.HK)公告,于2024财政年度,公司录得收入人民币2.78亿元,同比增长19.6%。尽管受批量采购价格影响及市场竞争导致毛利率下降,公司税前亏损大幅收窄至人民币1200万元,同比减少88.3%。随着业务规模扩张及成本控制与增效措施成效显现,销售及分销开支与行政开支的费用率降至49.6%(2023年:66.2%)。
年内,为适应快速变化的市场环境,公司持续推动神经介入业务升级,聚焦差异化治疗器械。急性缺血性脑卒中治疗器械(如颅内取栓支架、远端通路导管、颅内血栓抽吸导管及支撑导管等)销量增长45.5%。出血性脑卒中治疗器械及其他介入通路器械收入分别增长104.2%及109.4%。
于海外市场,公司已取得颅内取栓支架、封堵球囊导管、远端通路导管及微导管的CE或FDA认证,以及26项其他国家或地区的注册证书。截至目前,公司正于10个国家或地区进行逾40项产品注册,扩展销售渠道,为实现海外销售长期目标奠定基础。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.